World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
34840
World Ranking
12087
National Ranking
6200

David M. Nanus publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David M. Nanus sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 491 publications — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David M. Nanus D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David M. Nanus sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

David M. Nanus is affiliated with Cornell University in the United States. Their research primarily focuses on cancer, with a significant emphasis on prostate cancer treatment and research. The scientist's work encompasses various related fields such as medicine, biochemistry, genetics, and molecular biology.

Their recent research outputs include studies published between 2020 and 2021, highlighting advances in understanding prostate cancer and its treatment modalities. Notable papers include:

  • Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer, 2020, Journal of Clinical Investigation
  • A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer, 2020, Clinical Cancer Research
  • Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer, 2021, Nature Communications
  • Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer, 2020, JCO Precision Oncology
  • SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy, 2020, Molecular Cancer Therapeutics

David M. Nanus collaborates regularly with several frequent co-authors, including:

  • Scott T. Tagawa
  • Cora N. Sternberg
  • Ana M. Molina
  • Jones T. Nauseef
  • Joseph R. Osborne

The scientist's publications appear predominantly in high-impact academic venues such as:

  • Journal of Clinical Oncology
  • Cancer Research
  • The Journal of Urology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Annals of Oncology

Their work covers a range of subfields including pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, cancer research, oncology, and molecular biology. Major research topics include:

  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Diagnosis and Treatment
  • Medical Imaging Techniques and Applications
  • Cancer, Lipids, and Metabolism

David M. Nanus has been recognized as a member of the Association of American Physicians, reflecting professional acknowledgment within their field.

Best Publications

  • Integrative clinical genomics of advanced prostate cancer

    Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Renal-cell carcinoma.

    Robert J. Motzer;Neil H. Bander;David M. Nanus

  • Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

    Himisha Beltran;Himisha Beltran;Davide Prandi;Juan Miguel Mosquera;Juan Miguel Mosquera;Matteo Benelli

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

    Himisha Beltran;David S. Rickman;Kyung Park;Sung Suk Chae

  • Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

    Neil H. Bander;Matthew Ivan Milowsky;David M. Nanus;Lale Kostakoglu

  • Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

    Himisha Beltran;Roman Yelensky;Garrett M. Frampton;Kyung Park

  • Erratum: Integrative Clinical Genomics of Advanced Prostate Cancer

    Dan Robinson;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz

  • Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    Maha H.A. Hussain;Gary R. MacVicar;Daniel P. Petrylak;Rodney L. Dunn

  • Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.

    Jason P. Gleghorn;Erica D. Pratt;Denise Denning;He Liu

  • Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

    Medha S Darshan;Matthew S Loftus;Maria Thadani-Mulero;Ben P Levy

  • Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer

    Scott T. Tagawa;Matthew I. Milowsky;Michael Morris;Shankar Vallabhajosula

  • Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression.

    Papandreou Cn;Usmani B;Geng Y;Bogenrieder T

  • Phase I Trial of Yttrium-90--Labeled Anti--Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer

    Matthew I. Milowsky;David M. Nanus;Lale Kostakoglu;Shankar Vallabhajosula

  • Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression.

    Guenther A. Gastl;John S. Abrams;David M. Nanus;Rianne Oosterkamp

  • Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma

    Robert J. Motzer;Barbara A. Murphy;Jennifer Bacik;Lawrence H. Schwartz

  • Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset.

    D O Hardy;H I Scher;T Bogenreider;P Sabbatini

  • Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

    Kevin A. David;Matthew Ivan Milowsky;Jamie Ritchey;Peter R. Carroll

  • Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors

    Matthew Ivan Milowsky;David M. Nanus;Lale Kostakoglu;Christine E. Sheehan

  • Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets.

    H. Beltran;D. Rickman;K. Park;A. Sboner

Frequent Co-Authors

Himisha Beltran
Himisha Beltran Harvard University
Neil H. Bander
Neil H. Bander Cornell University
Mark A. Rubin
Mark A. Rubin University of Bern
Juan Miguel Mosquera
Juan Miguel Mosquera Cornell University
Stanley J. Goldsmith
Stanley J. Goldsmith Cornell University
Paul J. Christos
Paul J. Christos Cornell University
Andrea Sboner
Andrea Sboner Cornell University
Olivier Elemento
Olivier Elemento Cornell University
Lorraine J. Gudas
Lorraine J. Gudas Cornell University
Francesca Demichelis
Francesca Demichelis University of Trento

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to a range of online degrees and career options beyond the traditional MD. For nurses seeking advanced roles, the best online bsn to dnp programs provide flexible pathways to earn a Doctor of Nursing Practice (DNP) degree, combining clinical skills with leadership training.

If you're interested in pharmaceuticals, pharmacy school online options make it possible to start or advance your pharmacy career with accredited, remote study. For those drawn to healthcare technology and data, an online health information management degree can lead to roles managing patient records and healthcare information systems.

Entry-level programs like medical billing and coding online courses cost comparatively less and offer a fast track to jobs in healthcare administration, all from the comfort of your home. These online pathways provide flexibility, affordability, and a variety of opportunities to build your healthcare career without relocating or pausing your current commitments.

Best Scientists Citing David M. Nanus

Trending Scientists

Recently Published Articles